Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer (ANTiCIPe)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to develop an ultra sensitive assay of mutation detection on circulating tumor DNA (ctDNA) for treatment, diagnosis and monitoring disease progression of Non-Small Cell Lung Cancer (NSCLC).
Condition or disease
Stage IIIb and IV Non Small Cell Lung Cancer
Other: laboratory biomarker analysisOther: Next Generation SequencingGenetic: DNA Analysis
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Participants will be recruited from patients receiving treatment for NSCLC at the Rennes Hospital
Signed written informed consent
Male or female aged >= 18 years
Stage IIIb and IV Non Small Cell Lung Cancer histologically confirmed
Tissue and plasma samples can not be provided for mutation analysis
Unwilling or unable to provide informed consent
Any serious medical condition that would interfere with the subject's safety